Tolerability and Safety of Eflornithine (DFMO) in High-Risk Neuroblastoma (HRNB) Patients Treated with DFMO Maintenance Therapy
Tolerability and Safety of Eflornithine (DFMO) in High-Risk Neuroblastoma (HRNB) Patients Treated with DFMO Maintenance Therapy Jaqueline Kraveka, William Ferguson, Genevieve Bergendahl, Thomas Clinch, Elizabeth Lorenzi, Donald A. Berry, Javier Oesterheld,[...]
Subset Analysis of the role of MYCN in DFMO treated patients
Subset Analysis of the role of MYCN in DFMO treated patients Giselle Saulner Sholler, William Ferguson, Genevieve Bergendahl, Thomas Clinch, Elizabeth Lorenzi, Donald A. Berry, Javier Oesterheld, Valerie I. Brown, Don[...]
Sensitivity Analyses of Event Free and Overall Survival in High-Risk Neuroblastoma Patients Receiving Eflornithine (DFMO) Maintenance Treatment with Matched External Controls
Sensitivity Analyses of Event Free and Overall Survival in High-Risk Neuroblastoma Patients Receiving Eflornithine (DFMO) Maintenance Treatment with Matched External Controls, Giselle Saulner Sholler, William Ferguson, Genevieve Bergendahl, Thomas Clinch, Elizabeth[...]
Molecular-guided therapy for the treatment of relapsed neuroblastoma: A Beat Childhood Cancer Research Consortium Trial
Giselle L. Saulnier Sholler, MD, MS1, Elizabeth C. Lewis1, Jacqueline Kraveka, DO2, William Ferguson, MD3, Abhinav B. Nagulapally, MS1, Karl Dykema1, Genevieve Bergendahl, MSN1, Valerie I. Brown, MD, PhD4, Michael[...]
Development of Clinical-Grade Antibodies against Tumor-Specific Mutations to Target Neuroblastoma
Stephanie C. Pero, Abhinav B. Nagulapally, Linda Mei, Fan Zhang,*, Giselle S. Sholler, David N. Krag, Girja S. Shukla, Development of Clinical-Grade Antibodies against Tumor-Specific Mutations to Target Neuroblastoma, Annals of[...]
Comparison of Event Free Survival EFS) in High-Risk Neuroblastoma (HRNB) patients receiving Eflornithine (DFMO) Maintenance to an external control immunotherapy study database
Comparison of Event Free Survival EFS) in High-Risk Neuroblastoma (HRNB) patients receiving Eflornithine (DFMO) Maintenance to an external control immunotherapy study database, Javier E. Oesterheld, Genevieve Bergendahl, Donald A. Berry,[...]
Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance
Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance. Javier E. Oesterheld, Genevieve Bergendahl, Donald A. Berry, Elizabeth Lorenzi, Thomas Clinch, Jacqueline[...]
A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma
Giselle Saulnier Sholler, Dan G. Duda, Genevieve Bergendahl, David Ebb, Matija Snuderl, Theodore W. Laetsch, Jennifer Michlitsch, Derek Hanson, Michael S. Isakoff, Kevin Bielamowicz, Jacqueline M. Kraveka, William Ferguson, Peter[...]
The Cellular Effects of Physiologic Dosing of DFMO in Neuroblastoma Tumorigenesis
Mulama H. David, Divya Gandra1, Kimberly Q. McKinney, David M. Foureau, Kaitlyn Smith, Jason Haw, Giselle Saulnier Sholler, The Cellular Effects of Physiologic Dosing of DFMO in Neuroblastoma Tumorigenesis, 2022, ASPHO Annual[...]
Utilizing transcriptome analysis to identify targeted therapy for Ewing sarcoma
Smith, K, Gandra, D, McKinney, K, Dykema, K, Nagulapally, A, Mulama, D, Sholler, GS, Oesterheld, J, Trovillion, E. Utilizing transcriptome analysis to identify targeted therapy for Ewing sarcoma. (2022), ASPHO Annual Meeting,[...]